Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
Crossref DOI link: https://doi.org/10.1007/s12325-017-0573-0
Published Online: 2017-06-19
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kohler, Sven
Zeller, Cordula
Iliev, Hristo
Kaspers, Stefan
Funding for this research was provided by:
Boehringer Ingelheim
Text and Data Mining valid from 2017-06-19
Article History
Received: 22 May 2017
First Online: 19 June 2017